Monograph Details
|
|
Neoplasms
> Alkylating agents
|
|
CEENU |
| Manufacturer |
|
Bristol-Myers Squibb |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Alkylating agent. |
| Generic Name |
|
Lomustine 10mg, 40mg, 100mg; caps. |
| Indications |
|
Primary and metastatic brain tumors, in patients who have already received appropriate surgery and radiotherapy. Secondary therapy for Hodgkin's disease in combination with other approved drugs in patients who relapse while being treated or who fail primary therapy. |
| Adults and Children |
|
Pretreat with antiemetics and give on empty stomach. Give one dose every 6 weeks. Previously untreated (as a single agent): 130mg/m2. Compromised bone marrow function: 100mg/m2. Combination with other myelosuppressive drugs: adjust doses accordingly. Subsequent doses: adjust according to hematologic response (see literature). |
| Precautions |
|
Monitor blood counts weekly for ≥6 weeks after a dose; repeat courses should not be given before 6 weeks (delayed hematologic toxicity) or until platelets are >100,000/mm3 or leukocytes >4000/mm3. Monitor liver and renal function. Perform pulmonary function tests prior to and frequently during therapy; increased risk of pulmonary toxicity in patients with baseline <70% of the predicted Forced Vital Capacity or Carbon Monoxide Diffusing Capacity. Pregnancy (Cat.D). Nursing mothers: not recommended. |
| Adverse Reactions |
|
Delayed or cumulative myelosuppression (thrombocytopenia, leukopenia) leading to infection or bleeding, pulmonary toxicity, delayed pulmonary fibrosis, secondary malignancies, liver and renal dysfunction, nausea, vomiting, stomatitis, alopecia, optic atrophy, visual disturbances, disorientation, lethargy, ataxia, dysarthria. |
| Extra Text |
|
Note: Wear gloves when handling capsules. |
| How Supplied |
Caps—20
Dose pack (100mg–2 caps, 40mg–2 caps, 10mg–2 caps)—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
